Lantern Pharma Showcases AI-Driven Cancer Drug Development Pipeline in New Presentation

Reuters2025-11-04

Lantern Pharma Showcases AI-Driven Cancer Drug Development Pipeline in New Presentation

Lantern Pharma Inc. (NASDAQ: LTRN) has released a presentation detailing its current drug development pipeline and the role of its proprietary AI platform, RADR®, in accelerating oncology drug discovery. The presentation highlights Lantern's portfolio of drug candidates, including LP-300, which is in Phase 2 trials for non-small cell lung cancer in never smokers, and LP-184 and LP-284, which target various cancer indications and are at different stages of clinical development. The company reports that its AI-driven approach has enabled significant reductions in early-stage development timelines and costs, as well as high accuracy in patient stratification for clinical trials. The presentation also outlines Lantern's ongoing clinical trials, collaborations, and opportunities for partnering and licensing with other biopharma and technology companies. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580496802?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 02:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580496802","market":"nz","top_or_hot":-1,"title":"Lantern Pharma Showcases AI-Driven Cancer Drug Development Pipeline in New Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lantern Pharma Showcases AI-Driven Cancer Drug Development Pipeline in New Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LTRN\">Lantern Pharma Inc.</a> (NASDAQ: LTRN) has released a presentation detailing its current drug development pipeline and the role of its proprietary AI platform, RADR®, in accelerating oncology drug discovery. The presentation highlights Lantern's portfolio of drug candidates, including LP-300, which is in Phase 2 trials for non-small cell lung cancer in never smokers, and LP-184 and LP-284, which target various cancer indications and are at different stages of clinical development. The company reports that its AI-driven approach has enabled significant reductions in early-stage development timelines and costs, as well as high accuracy in patient stratification for clinical trials. The presentation also outlines Lantern's ongoing clinical trials, collaborations, and opportunities for partnering and licensing with other biopharma and technology companies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lantern Pharma Showcases AI-Driven Cancer Drug Development Pipeline in New Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLantern Pharma Showcases AI-Driven Cancer Drug Development Pipeline in New Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 02:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lantern Pharma Showcases AI-Driven Cancer Drug Development Pipeline in New Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LTRN\">Lantern Pharma Inc.</a> (NASDAQ: LTRN) has released a presentation detailing its current drug development pipeline and the role of its proprietary AI platform, RADR®, in accelerating oncology drug discovery. The presentation highlights Lantern's portfolio of drug candidates, including LP-300, which is in Phase 2 trials for non-small cell lung cancer in never smokers, and LP-184 and LP-284, which target various cancer indications and are at different stages of clinical development. The company reports that its AI-driven approach has enabled significant reductions in early-stage development timelines and costs, as well as high accuracy in patient stratification for clinical trials. The presentation also outlines Lantern's ongoing clinical trials, collaborations, and opportunities for partnering and licensing with other biopharma and technology companies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LTRN","symbol_name":"Lantern Pharma Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL4wvQZQ:1","article_id":"2580496802","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580496802","pubTimestamp":1762193743,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lantern Pharma Inc.  has released a presentation detailing its current drug development pipeline and the role of its proprietary AI platform, RADR, in accelerating oncology drug discovery. The presentation highlights Lantern's portfolio of drug candidates, including LP-300, which is in Phase 2 trials for non-small cell lung cancer in never smokers, and LP-184 and LP-284, which target various cancer indications and are at different stages of clinical development. The company reports that its AI-driven approach has enabled significant reductions in early-stage development timelines and costs, as well as high accuracy in patient stratification for clinical trials. The presentation also outlines Lantern's ongoing clinical trials, collaborations, and opportunities for partnering and licensing with other biopharma and technology companies. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LTRN":"Lantern Pharma Inc.","BK4139":"生物科技"},"translate_title":"Lantern Pharma在新演示中展示了人工智能驱动的癌症药物开发管道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LTRN":0.9},"content_text":"Lantern Pharma Showcases AI-Driven Cancer Drug Development Pipeline in New Presentation\n    \n\nLantern Pharma Inc. (NASDAQ: LTRN) has released a presentation detailing its current drug development pipeline and the role of its proprietary AI platform, RADR®, in accelerating oncology drug discovery. The presentation highlights Lantern's portfolio of drug candidates, including LP-300, which is in Phase 2 trials for non-small cell lung cancer in never smokers, and LP-184 and LP-284, which target various cancer indications and are at different stages of clinical development. The company reports that its AI-driven approach has enabled significant reductions in early-stage development timelines and costs, as well as high accuracy in patient stratification for clinical trials. The presentation also outlines Lantern's ongoing clinical trials, collaborations, and opportunities for partnering and licensing with other biopharma and technology companies. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580496802","isCrawlerRequest":true}